Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth

Remus Pharmaceuticals reported H1 FY27 consolidated revenue of ₹614.12 Cr, up 53.45% YoY and 35.44% vs H2 FY26

Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth

Remus Pharmaceuticals Ltd · Press Release · 03 Nov 2026, 9:46 pm

Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth Remus Pharmaceuticals reported H1 FY27 consolidated revenue of ₹614.12 Cr, up 53.45% YoY and 35.44% vs H2 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 Cr, while PAT grew 14.22% YoY to ₹24.66 Cr, impacted by setup and operating costs across Bolivia, Guatemala, and Espee GCTS subsidiaries. Standalone revenue jumped 32.51% YoY to ₹62.08 Cr, with PAT expanding 56.37% YoY to ₹18.81 Cr. Key operational milestones include securing Semaglutide approvals, winning a 24-product tender in Bolivia, and obtaining DIGEMID plant approval in Peru.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements